Immune checkpoint inhibitor-related pneumonitis following discontinuation of pembrolizumab in a patient with advanced lung adenocarcinoma: a case report and literature review

Abstract Background Checkpoint inhibitor-related pneumonitis (CIP) is a rare but serious complication of immune checkpoint inhibitors (ICIs). While it typically occurs within the first few months of treatment, its onset after ICI discontinuation is relatively uncommon. This report presents a case of...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Huan Wang, Yuzhen Jin, Peng Liu, Jie Zhou, Na Fan, Mengjie Li
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2024-12-01
coleção:	BMC Pulmonary Medicine
Assuntos:	Lung adenocarcinoma Immune checkpoint inhibitors Checkpoint inhibitor-related pneumonitis Pembrolizumab
Acesso em linha:	https://doi.org/10.1186/s12890-024-03424-9
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!